Will Stratton

Will Stratton is the Chief Business Officer and Head of Strategy and Planning at Autobahn Therapeutics, a San Diego biotech building brain-targeting small molecules for neuropsychiatric and neuroimmunologic disorders. A Yale chemist turned Wharton-trained dealmaker, he helped steer the company's oversubscribed $100 million Series C in 2024 and runs the corporate strategy behind a pipeline led by ABX-002, a thyroid hormone receptor beta agonist for depression.